Cancer Research

UCLA Inventors Earn Top Honor for Lifesaving Work
Research & Development UCLA Inventors Earn Top Honor for Lifesaving Work

The translation of profound academic research into tangible technologies that address humanity's most pressing challenges stands as a hallmark of institutional excellence, a commitment exemplified by the University of California, Los Angeles. In a significant recognition of this mission, two

Many Seniors With Disabilities Reject the Label
Research & Development Many Seniors With Disabilities Reject the Label

The home of Barbara and Dennis Meade in Ypsilanti, Michigan, is filled with the unmistakable artifacts of significant health challenges, from the walkers and wheelchairs to the oxygen tanks required for Barbara's chronic respiratory disease. Yet despite these daily realities and their shared,

Can Heart Valve Treatment Improve Cancer Survival?
Research & Development Can Heart Valve Treatment Improve Cancer Survival?

A groundbreaking analysis presented at the European Association of Cardiovascular Imaging 2025 congress has shed new light on a critical and burgeoning field of medicine, revealing that treating valvular heart disease in cancer patients can dramatically improve their survival rates. As remarkable

Cancer Hijacks Death Pathway to Resist Treatment
Research & Development Cancer Hijacks Death Pathway to Resist Treatment

The perplexing and often heartbreaking phenomenon of cancer recurrence following initially successful treatment has long been a central challenge in oncology, driving a significant number of cancer-related fatalities worldwide. Patients and clinicians are frequently confronted with the reality that

Could Tucatinib Change HER2+ Breast Cancer Care?
Research & Development Could Tucatinib Change HER2+ Breast Cancer Care?

Today, we have the privilege of speaking with Ivan Kairatov, a biopharma expert with extensive experience in oncology research and development. We'll be dissecting the groundbreaking results from the HER2CLIMB-05 trial, a study that introduces a significant potential shift in the first-line

New Drug Prevents More Breast Cancer Recurrences
Research & Development New Drug Prevents More Breast Cancer Recurrences

An extensive analysis of a recent international study highlights a significant advancement in treating early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer, which is the most common subtype affecting approximately 70% of all patients. The landmark lidERA clinical trial

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later